<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nafcillin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nafcillin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nafcillin: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9674" href="/d/html/9674.html" rel="external">see "Nafcillin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10885" href="/d/html/10885.html" rel="external">see "Nafcillin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1048812"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Penicillin (Antistaphylococcal)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462511"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, non-CNS involvement:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gestational age-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: IM, IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Gestational Age</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Postnatal Age</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">≤34 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">&gt;34 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 6 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: IM, IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Body Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Postnatal Age</p></th>
<th align="center">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">&lt;1 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤14 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">37.5 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">1 to 2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">37.5 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">&gt;2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">37.5 mg/kg/dose every 6 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy: </i>Empiric therapy for late-onset sepsis may generally be discontinued when blood cultures are negative at 24 to 48 hours unless there is evidence of site-specific infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25425653','lexi-content-ref-34490157','lexi-content-ref-21037285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25425653','lexi-content-ref-34490157','lexi-content-ref-21037285'])">Ref</a></span>). For confirmed infections, treatment duration depends on pathogen, site of infection, adequacy of source control, and clinical response. Uncomplicated methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) bacteremia can typically be treated for 10 to 14 days; longer durations may be necessary for persistent or complicated bacteremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mukhopadhyay.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mukhopadhyay.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea65a8b1-e322-4417-b372-ae2b2b3d970d">Meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis:</b> Limited data available: <b>Note</b>: Duration of therapy for meningitis caused by gram-positive pathogens is typically 14 to 21 days; individualize therapy based on patient factors including clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-15494903','lexi-content-ref-Mukhopadhyay.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-15494903','lexi-content-ref-Mukhopadhyay.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-15494903'])">Ref</a></span>): IM, IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Body Weight</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Postnatal Age</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">&lt;1 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤14 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">1 to 2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">&gt;2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 6 hours</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dop drugH1Div" id="F199193"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Traditional (intermittent) dosing:</i> Infants, Children, and Adolescents: IM, IV: 100 to 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b> divided every 4 hours; usual maximum dose: 2,000 mg/dose; for severe infections, doses at the higher end of the range should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion dosing</i>: Limited data available: Children and Adolescents: IV: 150 to 200 mg/kg/day infused continuously over 24 hours; maximum daily dose: 12 <b>g/day</b>. Dosing based on a retrospective case series in 40 pediatric patients (median age: 9 years; interquartile range: 2.3 to 12 years); the reported mean dose was 190 ± 36.4 mg/kg/day; the majority of infections treated were methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) (87.2% of patients) and coagulase negative staphylococcal species (7.7%); infection sites were primarily bloodstream, musculoskeletal, and skin and soft tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28943820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28943820'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>): Children and Adolescents: IV: 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b> divided every 4 hours; treat for at least 4 weeks; longer durations may be necessary; may use in combination with gentamicin for some resistant organisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88786394-7fdd-4d67-b085-e61870ea2bdf">Meningitis, including health care-associated ventriculitis/meningitis; MSSA</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, including health care-associated ventriculitis/meningitis; MSSA:</b> Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g/day</b>; usual maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">MSSA: IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g/day</b>; usual maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Necrotizing infection due to MSSA: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g/day</b>; usual maximum dose: 2,000 mg/dose; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Streptococcal skin infections: Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g/day</b>; usual maximum dose: 2,000 mg/dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130408"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: No dosage adjustment is necessary unless renal impairment is in the setting of concomitant hepatic impairment then use with caution; specific adjustment for combined renal and hepatic impairment is not provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51130409"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be necessary particularly in the setting of concomitant renal impairment; nafcillin primarily undergoes hepatic metabolism. In patients with both hepatic and renal impairment, monitoring of serum drug concentrations and modification of dosage may be necessary.</p></div>
<div class="block doa drugH1Div" id="F199179"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9674" href="/d/html/9674.html" rel="external">see "Nafcillin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>IV:</b> 1 to 2 g every 4 to 6 hours; may also administer total daily dose as a continuous infusion over 24 hours (eg, for a dose of 2 g every 4 hours, administer 12 g over 24 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.1','lexi-content-ref-27485941','lexi-content-ref-26229122','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.1','lexi-content-ref-27485941','lexi-content-ref-26229122','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection: </b>
<i> Pathogen-directed therapy for methicillin-susceptible staphylococci (off label):</i>
<b> IV:</b> 2 g every 4 hours; treat uncomplicated bacteremia for ≥14 days starting from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b>
<i>Pathogen-directed therapy for</i>
<i>methicillin-susceptible staphylococci (off label):</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Native valve:</i>
<b>IV: </b>12 g/day in 4 or 6 divided doses (ie, 2 g every 4 hours or 3 g every 6 hours) for 6 weeks. For uncomplicated right-sided IE, 2 weeks of therapy may be adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prosthetic valve:</i>
<b>IV: </b>12 g/day in 6 divided doses (ie, 2 g every 4 hours) for ≥6 weeks (use with rifampin for entire duration of therapy and gentamicin for first 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial:</b>
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci (off label)</i>
<i>: </i>
<b>IV:</b> 2 g every 4 hours; consider addition of rifampin if organism is susceptible and prosthetic material is present. Treatment duration is 10 to 14 days, depending on causative pathogen(s) and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c92ca38-0c20-4ec4-b5f0-113c6ccf7cd2">Osteomyelitis and/or discitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis and/or discitis:</b>
<i>Pathogen-directed therapy for</i>
<i>methicillin-susceptible staphylococci (off label):</i>
<b>IV:</b> 1.5 to 2 g every 4 to 6 hours or via continuous infusion for ≥6 weeks depending on extent of infection, debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b>
<i>Pathogen-directed therapy for</i>
<i>methicillin-susceptible staphylococci (off label)</i>
<i>: </i>
<b>IV:</b> 2 g every 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1'])">Ref</a></span>). Minimum duration is generally 5 days for community-acquired pneumonia and 7 days for hospital-acquired or ventilator-associated pneumonia; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577','lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577','lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection:</b>
<i>Pathogen-directed therapy for</i>
<i>methicillin-susceptible staphylococci (off label):</i>
<b>IV:</b> 1.5 to 2 g every 4 to 6 hours; duration ranges from 2 to 6 weeks depending on prosthesis management, use of rifampin, and other patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cellulitis (nonpurulent) in patients without risk for methicillin-resistant S. aureus: </i>
<b>IV</b>: 1 to 2 g every 4 hours. Total duration of therapy is ≥5 days (including oral step-down therapy); may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Necrotizing infection due to methicillin-susceptible S. aureus (MSSA) (off label):</i>
<b> IV:</b> 1 to 2 g every 4 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical site incisional infection (trunk or extremity, not involving axilla or perineum) (off label):</i>
<b>IV:</b> 2 g every 6 hours; duration is dependent upon severity, need for debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992025"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In one retrospective review of patients receiving continuous nafcillin infusions, increased SCr was associated with decreased nafcillin clearance; increased nafcillin concentrations were associated with increased incidence of adverse drug reactions (hepatotoxicity, nausea/vomiting, and diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27485941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27485941'])">Ref</a></span>); periodically assess for tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-883823','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-883823','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-883823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-883823'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-883823','lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-883823','lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989317"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Nafcillin primarily undergoes hepatic metabolism; dosage adjustment may be necessary, particularly in the setting of concomitant renal impairment.</p></div>
<div class="block adr drugH1Div" id="F199145"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous rash (Chang 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Guido 2017), <i>Clostridioides difficile</i>-associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Markowitz 1975), bone marrow depression, neutropenia (Chang 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Guido 2017), increased serum transaminases (Guido 2017; Khatib 2021), jaundice (Guido 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Nguyen 2019), hypersensitivity angiitis (Xie 2015), hypersensitivity reaction (Blumenthal 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site, injection-site phlebitis, local desquamation (injection site), pain at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Bodendorfer 1980), renal tubular disease</p></div>
<div class="block coi drugH1Div" id="F199161"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to nafcillin, other penicillins, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F199142"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or a history of sensitivity to multiple allergens. Use with caution in patients with a history of significant allergies and/or asthma; discontinue treatment and institute appropriate therapy if an allergic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; avoid extravasation of IV infusions; ensure proper catheter or needle position prior to and during infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Elevation of liver transaminases and/or cholestasis may occur, specifically with high doses. Reevaluate use in patients who develop worsening hepatic function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Hypokalemia has been observed in pediatric and adult patients. In a retrospective cohort study comparing tolerability of maximum daily dosing (12 g) of nafcillin and oxacillin in adults (n=224; median age: 56 years; range: 19 to 90 years), the observed incidences of hypokalemia (≤3.3 mmol/L), severe hypokalemia (≤2.9 mmol/L), and acute decreases (≥0.5 mmol/L) from baseline of serum potassium were significantly higher in the nafcillin group compared to oxacillin; median time to onset was 3 to 4 days (Viehman 2016). While a similar level of comparison has not been reported in pediatric patients, hypokalemia has been observed with nafcillin therapy in pediatric patients. In a study of children and adolescents receiving continuous infusion nafcillin at a mean dose of 190 ± 36.4 mg/kg/day, hypokalemia developed in 3 (7.5%) subjects (Knoderer 2017). Hypokalemia was also reported in a retrospective review of 30 pediatric patients with malignancies who received nafcillin in combination with carbenicillin and gentamicin; hypokalemia was reported in 50% (24/48) of antibiotic courses and usual reported onset was 4 days of therapy (Stapleton 1976).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxic effects: Large IV or intraventricular doses have been associated with neurotoxicity; use caution, especially in patients with concomitant renal and hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: May contain a significant amount of sodium; use with caution in patients with heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic/renal impairment: Use with caution in patients with concomitant hepatic and renal impairment.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878558"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In a study of pediatric patients (5 to 19 years) receiving outpatient nafcillin for &gt;3 weeks, significantly less rash was reported in the nafcillin group (10.3%) compared to oxacillin group (31.7%) (Maraqa 2002).</p></div>
<div class="block dosfc drugH1Div" id="F50470565"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Nafcillin lyophilized powder contains sodium approximately 66 mg [2.9 mEq] per gram of nafcillin.</p>
<p style="text-indent:-2em;margin-left:2em;">Nafcillin in Dextrose (iso-osmotic) contains sodium 76.6 mg [3.33 mEq] per gram of nafcillin.</p></div>
<div class="block foc drugH1Div" id="F199154"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea [DSC]); 2 g (1 ea [DSC]); 10 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F199138"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323444"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nafcillin Sodium in Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 gm/50 mL (per mL): $0.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/100 mL (per mL): $0.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nafcillin Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $13.20 - $17.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $9.85 - $34.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nafcillin Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $132.00 - $174.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613382"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer reconstituted solution as deep intragluteal injection per manufacturer's labeling; appropriate injection site should take into consideration patient age, muscle development, and volume of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24201242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24201242'])">Ref</a></span>); only use intragluteal injection if appropriate; rotate injection sites.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Direct IV injection: Further dilute and administer over 5 to 10 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV infusion: Infuse over 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Children and Adolescents: Infuse daily dose over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28943820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28943820'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>); elevate extremity.</p></div>
<div class="block adm drugH1Div" id="F199158"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer as a deep intragluteal injection; rotate injection sites.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 30 to 60 minutes; may administer as a direct injection over 5 to 10 minutes. Total daily dose may also be administered over 24 hours as a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.1','lexi-content-ref-27485941','lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.1','lexi-content-ref-27485941','lexi-content-ref-26229122'])">Ref</a></span>). Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F199171"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Premixed infusions: Store in a freezer at  -20°C (-4°F). Thaw at room temperature or under refrigeration only. Thawed bags are stable for 21 days under refrigeration or 72 hours at room temperature. Do not refreeze.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Vials: Store at 20°C to 25°C (68°F to 77°F). Reconstituted parenteral solution is stable for 3 days at room temperature and 7 days when refrigerated. For IV infusion in NS or D<sub>5</sub>W, solution is stable for 24 hours at room temperature and 7 days when refrigerated.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solutions for ambulatory IV infusion reservoirs (eg, &gt;24-hour supply) may be subject to inadvertent exposure to temperatures higher than recommended due to heat radiation from patient's skin; lower concentrations of preparation may be needed to prevent precipitation of solution in some circumstances (Chan 2005). </p></div>
<div class="block usep drugH1Div" id="F53567945"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of bacterial infections such as osteomyelitis, septicemia, endocarditis, and CNS infections due to susceptible strains of <i>Staphylococcus</i> (FDA approved in pediatric patients [IM] and adults [IM and IV]).</p></div>
<div class="block cyt drugH1Div" id="F199195"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3; <b>Induces</b> CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F199147"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Acalabrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and moderate CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Apremilast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brexpiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inducers when possible. If combined, increase the daily dose of brigatinib in 30 mg increments after 7 days of treatment with the current brigatinib dose, up to maximum of twice the dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ceritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobicistat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Delavirdine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Doravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Duvelisib.  Management: Avoid if possible. If used, on day 12 of combination increase duvelisib from 25 mg twice daily to 40 mg twice daily or from 15 mg twice daily to 25 mg twice daily. Resume prior duvelisib dose 14 days after stopping moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Efavirenz. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Eliglustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elvitegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Encorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erdafitinib.  Management: Dose modifications of erdafitinib may be required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Exemestane. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fruquintinib.  Management: Avoid this combination when possible. If combined, continue the same fruquintinib dose, but monitor for reduced fruquintinib efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and moderate CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gemigliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gepirone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glasdegib.  Management: Avoid use of glasdegib and moderate CYP3A4 inducers whenever possible. If combined, increase glasdegib dose from 100 mg daily to 200 mg daily or from 50 mg daily to 100 mg daily. Resume previous glasdegib dose 7 days after discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Idelalisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and moderate CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Istradefylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixazomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Larotrectinib.  Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: Nafcillin may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levoketoconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of LinaGLIPtin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lopinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Moderate) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with moderate CYP3A4 inducers. If such a combination must be used, increase lorlatinib to 125 mg daily. Monitor for reduced lorlatinib efficacy and consider closer monitoring of AST, ALT, and bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maribavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mitapivat.  Management: Consider alternatives to this combination when possible. If combined, monitor hemoglobin and titrate mitapivat beyond 50 mg twice daily, if needed, but do not exceed doses of 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Netupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirmatrelvir and Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Osimertinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with moderate CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use if possible. If combined, if the current pirtobrutinib dose is 200 mg once daily, increase to 300 mg once daily. If current pirtobrutinib dose is 50 mg or 100 mg once daily, increase the dose by 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Praziquantel.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced praziquantel efficacy. If possible, stop the moderate CYP3A4 inducer 2 to 4 weeks before praziquantel initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ripretinib.  Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Moderate) may decrease the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritlecitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Samidorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sotorasib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tivozanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tolvaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Upadacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vandetanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Nafcillin may diminish the anticoagulant effect of Vitamin K Antagonists.  Management: Consider choosing an alternative antibiotic. Monitor for decreased therapeutic effects and need for dose adjustments of oral anticoagulants if nafcillin is initiated/dose increased, or increased effects if nafcillin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zaleplon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zanubrutinib.  Management: Avoid this combination if possible. If coadministration of zanubrutinib and a moderate CYP3A4 inducer is required, increase the zanubrutinib dose to 320 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F199163"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium. </p></div>
<div class="block pri drugH1Div" id="F5720663"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Penicillin class antibiotics cross the placenta in varying degrees. Nafcillin is highly protein bound which may limit fetal exposure (Nau 1987).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).</p></div>
<div class="block mopp drugH1Div" id="F53567935"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, urinalysis, BUN, SCr (baseline and periodic during prolonged therapy); serum potassium (baseline and periodic) (Knoderer 2017; Viehman 2016); serum bilirubin, AST, ALT, alkaline phosphatase, and gamma glutamyl transferase (baseline and periodic; especially when using high doses or during prolonged therapy). Observe for signs and symptoms of anaphylaxis. Monitor IV site for extravasation.</p></div>
<div class="block pha drugH1Div" id="F199141"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall destruction and resultant bactericidal activity against susceptible bacteria; resistant to inactivation by staphylococcal penicillinase  </p></div>
<div class="block phk drugH1Div" id="F199160"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed; CSF penetration is poor but enhanced by meningeal inflammation.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates (GA 28 to 33 weeks; PNA 5 to 68 days): 0.242 to 0.534 L/kg (Banner 1980).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤13 years of age: 0.893 ± 0.083 L/kg (Feldman 1978).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.57 to 1.55 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~90%; primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic; undergoes enterohepatic recirculation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates (GA 28 to 33 weeks) (Banner 1980):</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;3 weeks: 2.23 to 5.46 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≥3 to 9 weeks: 1.24 to 2.26 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents ≤13 years of age : 0.76 ± 0.03 hours (Feldman 1978).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Normal renal/hepatic function: 33 to 61 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces; urine (~30% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51159712"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma clearance is significantly decreased and excretion in urine was significantly increased from ~30% to 50% in patients with biliary obstruction and cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC); goal: ≥50% <i>f</i>T &gt; MIC (bactericidal) (Drusano 2003; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Critically ill patients in the ICU: Minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt; 4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Expected drug exposure in normal renal function:</p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max </sub>(peak): Single dose: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, children, and adolescents ≤13 years of age: 37.5 mg/kg (infused over 15 minutes): 48.1 ± 3.5 mg/L (Feldman 1978).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 500 mg (infused over 7 minutes): ~30 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Minimal bacterial killing continues after concentration of penicillins fall below the MIC of targeted pathogen and varies based on the organism:</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-positive cocci: 1.5 to 3.5 hours (Craig 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-negative bacilli: 0 to 1.5 hours (Craig 1991).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> Continuous infusion: Hospitalized adults: In a retrospective study, steady-state nafcillin concentrations were significantly higher in patients who experienced an adverse drug event compared to those who did not (66 vs 25.5 mg/L). Specifically, concentrations were higher in patients who experienced hepatotoxicity (62.8 vs 27 mg/L), nausea/vomiting (80 vs 28.5 mg/L), and diarrhea (66.5 vs 26.5 mg/L) (Benefield 2016).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58194609"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Apothecon nafcilli</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Vigopen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nafcil | Nafcillin | Unipen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nafcil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper.<i> Intensive Care Med</i>. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al; The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol.</i> 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22844299">
<a name="22844299"></a>Alam MB, Kadoura A, Sathaiah M. A Fatal Case of Nafcillin-Induced Hepatotoxicity: A Case Report and the Literature Review. <i>Case Report Med.</i> 2012;2012:953714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/22844299/pubmed" id="22844299" target="_blank">22844299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. <i>J Antimicrob Chemother</i>. 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7396459">
<a name="7396459"></a>Banner W Jr, Gooch WM 3d, Burckart G, et al. Pharmacokinetics of Nafcillin in Infants With Low Birth Weights. <i>Antimicrob Agents Chemother</i>. 1980;17(4):691-694.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/7396459/pubmed" id="7396459" target="_blank">7396459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bauer.1">
<a name="Bauer.1"></a>Bauer KA, West JE, Shidham G. An antimicrobial stewardship program’s evaluation of the safety and efficacy of continuous infusion of nafcillin in the treatment of methicillin-sensitive <i>Staphylococcus aureus</i> bacteremia. <i>Infect Dis Clin Pract</i>. 2013;21(2):111-113.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27485941">
<a name="27485941"></a>Benefield RJ, Barker BC, Gast CM, Alexander DP. Patient variables associated with nafcillin plasma concentrations and toxicity. <i>Pharmacotherapy</i>. 2016;36(9):994-1002. doi:10.1002/phar.1805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/27485941/pubmed" id="27485941" target="_blank">27485941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14658003">
<a name="14658003"></a>Blazes DL, Martin GJ. Drug Induced Lupus Erythematosus Secondary to Nafcillin: The First Reported Case. <i>Rheumatol Int</i>. 2004;24(4):242-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/14658003/pubmed" id="14658003" target="_blank">14658003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24637693">
<a name="24637693"></a>Blumenthal KG, Youngster I, Shenoy ES, Banerji A, Nelson SB. Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting. <i>Antimicrob Agents Chemother</i>. 2014;58(6):3137-3143. doi:10.1128/AAC.02504-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/24637693/pubmed" id="24637693" target="_blank">24637693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7431606">
<a name="7431606"></a>Bodendorfer TW. Nafcillin-induced interstitial nephritis. <i>JAMA</i>. 1980;244(23):2609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/7431606/pubmed" id="7431606" target="_blank">7431606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS, Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 29th ed. American Academy of Pediatrics; 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11430456">
<a name="11430456"></a>Carek PJ, Dickerson LM, Sack JL. Diagnosis and Management of Osteomyelitis. <i>Am Fam Physician</i>. 2001;63(12):2413-2420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/11430456/pubmed" id="11430456" target="_blank">11430456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15972371">
<a name="15972371"></a>Chan V. Influence of temperature and drug concentration on nafcillin precipitation. <i>Am J Health Syst Pharm</i>. 2005;62(13):1347-1348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/15972371/pubmed" id="15972371" target="_blank">15972371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22293804">
<a name="22293804"></a>Chang MO, Koh ES, Kim MJ, et al. Nafcillin-induced bullous skin eruption with granulocytopenia in a patient with end-stage renal disease. <i>Intern Med</i>. 2012;51(3):287-289. doi:10.2169/internalmedicine.51.6091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/22293804/pubmed" id="22293804" target="_blank">22293804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16891922">
<a name="16891922"></a>Cone LA, Lopez C, O’Connell SJ, et al. Staphylococcal Septic Synovitis of the Sternoclavicular Joint With Retrosternal Extension. <i>J Clin Rheumatol</i>. 2006;12(4):187-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/16891922/pubmed" id="16891922" target="_blank">16891922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1938689">
<a name="1938689"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiology Newsletter.</i> 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/1938689/pubmed" id="1938689" target="_blank">1938689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med.</i> 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9161625">
<a name="9161625"></a>Dahlgren AF. Adverse Drug Reactions in Home Care Patients Receiving Nafcillin or Oxacillin. <i>Am J Health Syst Pharm</i>. 1997;54(10):1176-1179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/9161625/pubmed" id="9161625" target="_blank">9161625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol.</i> 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-883823">
<a name="883823"></a>Diaz CR, Kane JG, Parker RH, Pelsor FR. Pharmacokinetics of nafcillin in patients with renal failure. <i>Antimicrob Agents Chemother</i>. 1977;12(1):98-101. doi:10.1128/AAC.12.1.98<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/883823/pubmed" id="883823" target="_blank">883823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25425653">
<a name="25425653"></a>Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2015;100(3):F257-F263. doi:10.1136/archdischild-2014-306213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/25425653/pubmed" id="25425653" target="_blank">25425653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR, Mandell GL. Beta-Lactam Antibiotics. <i>N Engl J Med</i>. 1988;318(7):419-26 and 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12516029">
<a name="12516029"></a>Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. <i>Clin Infect Dis.</i> 2003;36(suppl 1):S42-S50. doi:10.1086/344653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/12516029/pubmed" id="12516029" target="_blank">12516029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-722420">
<a name="722420"></a>Feldman WE, Nelson JD, Stanberry LR. Clinical and pharmacokinetic evaluation of nafcillin in infants and children. <i>J Pediatr.</i> 1978;93(6):1029-1033. doi:10.1016/s0022-3476(78)81251-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/722420/pubmed" id="722420" target="_blank">722420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34490157">
<a name="34490157"></a>Goldberg O, Sokolover N, Bromiker R, et al. Antibiotic discontinuation 24 h after neonatal late-onset sepsis work-up-a validated decision tree model. <i>Front</i>
<i>Pediatr</i>. 2021;9:693882. doi:10.3389/fped.2021.693882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/34490157/pubmed" id="34490157" target="_blank">34490157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al.G uidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother</i>. 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28725311">
<a name="28725311"></a>Guido MV, Jithpratuck W, Parks GE, Krishnaswamy G. Nafcillin-induced allergic eosinophilic cholestatic hepatitis. <i>Gastroenterology Res</i>. 2017;10(3):202-207. doi:10.14740/gr824w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/28725311/pubmed" id="28725311" target="_blank">28725311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33628683">
<a name="33628683"></a>Khatib S, Sabobeh T, Bock MD, Masoud A, Alallaf J. Nafcillin-induced hepatic injury: a case report and literature review. <i>Cureus</i>. 2021;13(1):e12817. doi:10.7759/cureus.12817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/33628683/pubmed" id="33628683" target="_blank">33628683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28943820">
<a name="28943820"></a>Knoderer CA, Karmire LC, Nichols KR. Clinical outcomes with continuous nafcillin infusions in children. <i>J Pediatr Pharmacol Ther</i>. 2017;22(4):261-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/28943820/pubmed" id="28943820" target="_blank">28943820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf.</i> 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24714850">
<a name="24714850"></a>Le A, Patel S. Extravasation of noncytotoxic drugs: a review of the literature. <i>Ann Pharmacother</i>. 2014;48(7):870-886. doi:10.1177/1060028014527820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/24714850/pubmed" id="24714850" target="_blank">24714850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation - A Hazard of Intravenous Therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17278083">
<a name="17278083"></a>Mandell LA, Wunderink RG, Anzueto A, et al .Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. <i>Clin Infect Dis</i>. 2007;44(suppl 2):27-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/17278083/pubmed" id="17278083" target="_blank">17278083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11731945">
<a name="11731945"></a>Maraqa NF, Gomez MM, Rathore MH, et al. Higher Occurrence of Hepatotoxicity and Rash in Patients Treated With Oxacillin, Compared With Those Treated With Nafcillin and Other Commonly Used Antimicrobials. <i>Clin Infect Dis</i>. 2002;34(1):50-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/11731945/pubmed" id="11731945" target="_blank">11731945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1173618">
<a name="1173618"></a>Markowitz SM, Rothkopf M, Holden FD, Stith DM, Duma RJ. Nafcillin-induced agranulocytosis. <i>JAMA</i>. 1975;232(11):1150-1152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/1173618/pubmed" id="1173618" target="_blank">1173618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol.</i> 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mukhopadhyay.1">
<a name="Mukhopadhyay.1"></a>Mukhopadhyay S, Puopolo KM. Bacterial and fungal infections. <i>Manual of Neonatal Care</i>. 9th ed. 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Nafcillin [prescribing information]. Princeton, NJ: Sandoz Inc; November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Nafcillin in Dextrose [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.2">
<a name="Sandoz.2"></a>Nafcillin pharmacy bulk package [prescribing information]. Princeton, NJ: Sandoz Inc; November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3301235">
<a name="3301235"></a>Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. <i>Dev Pharmacol Ther.</i> 1987;10(3):174-198. doi:10.1159/000457744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/3301235/pubmed" id="3301235" target="_blank">3301235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32045160">
<a name="32045160"></a>Nguyen M, Chen YC, Tartar D. Characteristics of patients hospitalized for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) at a Level 1 trauma center. <i>Dermatol Online J</i>. 2019;25(12):13030/qt98k1f6q4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/32045160/pubmed" id="32045160" target="_blank">32045160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141794">
<a name="33141794"></a>Ong J, Van Gerpen R. Recommendations for management of noncytotoxic vesicant extravasations. <i>J Infus Nurs</i>. 2020;43(6):319-343. doi:10.1097/NAN.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/33141794/pubmed" id="33141794" target="_blank">33141794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qua.1">
<a name="Qua.1"></a>Qua DA, Tan MJ. Hypokalemia Associated With Nafcillin Treatment. <i>Infect Dis Clin Pract</i>. 2009;17(2):130-131.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24201242">
<a name="24201242"></a>Rishovd A. Pediatric intramuscular injections: guidelines for best practice. <i>MCN Am J Matern Child Nurs</i>. 2014;39(2):107-112; quiz 113-4. doi:10.1097/NMC.0000000000000009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/24201242/pubmed" id="24201242" target="_blank">24201242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis.</i> 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3428165">
<a name="3428165"></a>Robinson DC, Cookson TL, Grisafe JA. Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients. <i>Drug Intell Clin Pharm</i>. 1987;21(12):985-989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/3428165/pubmed" id="3428165" target="_blank">3428165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21037285">
<a name="21037285"></a>Russell AB, Sharland M, Heath PT. Improving antibiotic prescribing in neonatal units: time to act. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2012;97(2):F141-F146. doi:10.1136/adc.2007.120709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/21037285/pubmed" id="21037285" target="_blank">21037285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17693345">
<a name="17693345"></a>Schulmeister L. Extravasation Management. <i>Semin Oncol Nurs</i>. 2007;23(3):184-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/17693345/pubmed" id="17693345" target="_blank">17693345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1067752">
<a name="1067752"></a>Stapleton FB, Nelson B, Vats TS, Linshaw MA. Hypokalemia associated with antibiotic treatment. Evidence in children with malignant neoplasms. <i>Am J Dis Child</i>. 1976;130(10):1104-1108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/1067752/pubmed" id="1067752" target="_blank">1067752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i>Clin Infect Dis</i>. 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis.<i> Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. Published online February 14, 2017. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976858">
<a name="26976858"></a>Viehman JA, Oleksiuk LM, Sheridan KR, et al. Adverse events lead to drug discontinuation more commonly among patients who receive nafcillin than among those who receive oxacillin. <i>Antimicrob Agents Chemother</i>. 2016;60(5):3090-3095.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26976858/pubmed" id="26976858" target="_blank">26976858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002. Accessed May 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10090000">
<a name="10090000"></a>Wright AJ. The Penicillins. <i>Mayo Clin Proc</i>. 1999;74(3):290-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/10090000/pubmed" id="10090000" target="_blank">10090000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26023584">
<a name="26023584"></a>Xie C, Pancholi SS, Armistead N. Nafcillin implicated in a case of cutaneous and gastrointestinal leukocytoclastic vasculitis. <i>J Clin Diagn Res</i>. 2015;9(4):OD06-OD7. doi:10.7860/JCDR/2015/12573.5839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/26023584/pubmed" id="26023584" target="_blank">26023584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1">
<a name="Zenk.1"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7315807">
<a name="7315807"></a>Zenk KE, Dungy CL, Greene CR.N afcillin Extravasation Injury: Use of Hyaluronidase as an Antidote. <i>Am J Dis Child</i>. 1981;135(12):1113-1114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafcillin-pediatric-drug-information/abstract-text/7315807/pubmed" id="7315807" target="_blank">7315807</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12626 Version 365.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
